NASDAQ:SRRKScholar Rock Stock Price, Forecast & News

$18.57

-0.44 (-2.31 %)

(As of 05/22/2020 04:00 PM ET)

Add

Compare

Today's Range

$18.19

Now: $18.57▼

$19.06

50-Day Range

$10.37

MA: $16.02▼

$19.01

52-Week Range

$6.95

Now: $18.57▼

$21.92

Volume97,368 shs

Average Volume102,186 shs

Market Capitalization$554.69 million

P/E RatioN/A

Dividend YieldN/A

Beta0.81

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, an inhibitor of the activation of transforming growth factor beta-1 to treat cancers resistant to checkpoint blockade therapies. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Scholar Rock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.00, Scholar Rock has a potential upside of 88.5% from its current price of $18.57.
Amount of Analyst Coverage
Scholar Rock has only been the subject of 1 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Scholar Rock has received 113 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Scholar Rock has received 132 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Scholar Rock has received 53.88% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote “Outperform” if you believe SRRK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Scholar Rock does not currently pay a dividend.
Dividend Growth
Scholar Rock does not have a long track record of dividend growth.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Scholar Rock insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.40% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.71% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Scholar Rock are expected to decrease in the coming year, from ($2.17) to ($2.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Scholar Rock is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Scholar Rock is -9.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Scholar Rock has a P/B Ratio of 5.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.56 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SRRK

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.scholarrock.com

Phone857-259-3860

Debt

Debt-to-Equity Ratio0.04

Current Ratio6.06

Quick Ratio6.06

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$20.49 million

Price / Sales27.07

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.30 per share

Price / Book5.63

Profitability

EPS (Most Recent Fiscal Year)($1.85)

Net Income$-51,000,000.00

Net Margins-255.69%

Return on Equity-49.59%

Return on Assets-30.26%

Miscellaneous

Employees65

Outstanding Shares29,870,000

Market Cap$554.69 million

Next Earnings Date8/12/2020 (Estimated)

OptionableNot Optionable

Receive SRRK News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.

Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions

How has Scholar Rock's stock been impacted by COVID-19 (Coronavirus)?

Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SRRK stock has increased by 25.0% and is now trading at $18.57. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Scholar Rock?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Scholar Rock.

When is Scholar Rock's next earnings date?

Scholar Rock is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Scholar Rock.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Corp (NASDAQ:SRRK) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.59. The company had revenue of $5.03 million for the quarter, compared to analysts' expectations of $19.35 million. Scholar Rock had a negative return on equity of 49.59% and a negative net margin of 255.69%. View Scholar Rock's earnings history.

What price target have analysts set for SRRK?

2 brokerages have issued 12-month price targets for Scholar Rock's stock. Their forecasts range from $35.00 to $35.00. On average, they anticipate Scholar Rock's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 88.5% from the stock's current price. View analysts' price targets for Scholar Rock.

Has Scholar Rock been receiving favorable news coverage?

Media stories about SRRK stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Scholar Rock earned a news impact score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutScholar Rock.

Who are some of Scholar Rock's key competitors?

Some companies that are related to Scholar Rock include Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Cortexyme (CRTX), Regenxbio (RGNX), Twist Bioscience (TWST), I-Mab (BDTX), Beam Therapeutics (BEAM), Mesoblast (MESO), Translate Bio (TBIO), Coherus Biosciences (CHRS), NanoString Technologies (NSTG) and Passage Bio (PASG). View all competitors.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Coherus Biosciences (CHRS), Exelixis (EXEL), Global Blood Therapeutics (GBT), Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD).

Who are Scholar Rock's key executives?

Scholar Rock's management team includes the following people:

Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 54)
Mr. Yung H. Chyung, Chief Medical Officer (Age 43)
Ms. Rhonda M. Chicko, Chief Financial Officer (Age 53)
Mr. Alan J. Buckler, Chief Scientific Officer (Age 59)
Ms. Catherine Hu, Exec. Director of Investor Relations & Corp. Communications

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by a variety of institutional and retail investors. Top institutional investors include Redmile Group LLC (9.68%), BlackRock Inc. (4.15%), State Street Corp (1.21%), Victory Capital Management Inc. (0.97%), Victory Capital Management Inc. (0.97%) and Geode Capital Management LLC (0.85%). Company insiders that own Scholar Rock stock include Amir Nashat and International SCA Artal. View institutional ownership trends for Scholar Rock.

Which institutional investors are selling Scholar Rock stock?

SRRK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Redmile Group LLC, BlackRock Inc., UBS Group AG, Squarepoint Ops LLC, Alberta Investment Management Corp, and Wells Fargo & Company MN. View insider buying and selling activity for Scholar Rock.

Which institutional investors are buying Scholar Rock stock?

SRRK stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Morgan Stanley, Victory Capital Management Inc., Victory Capital Management Inc., Invesco Ltd., Russell Investments Group Ltd., Los Angeles Capital Management & Equity Research Inc., and Geode Capital Management LLC. Company insiders that have bought Scholar Rock stock in the last two years include Amir Nashat, and International SCA Artal. View insider buying and selling activity for Scholar Rock.

How do I buy shares of Scholar Rock?

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $18.57.

How big of a company is Scholar Rock?

Scholar Rock has a market capitalization of $554.69 million and generates $20.49 million in revenue each year. The company earns $-51,000,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Scholar Rock employs 65 workers across the globe.

What is Scholar Rock's official website?

The official website for Scholar Rock is www.scholarrock.com.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff